SCHEMBL2736726

SCHEMBL2736726

CCCCn1cc(-c2ccccc2)cc(NC(=O)c2ccccc2Cl)c1=O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.62
LMNA P02545 1/20 0.50
HPGD P15428 3/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
DCTPP1 Q9H773 1/20 0.48
SMO Q99835 2/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
PTGES O14684 1/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
F2 P00734 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
POLB P06746 1/20 0.44
WDR5 P61964 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2760181 0.88 CNR2 (0.64) CNR2HPGDHTTCYP1A2CYP2C19
SCHEMBL2736728 0.83 CNR2 (0.59) CNR2LMNAHPGDALDH1A1KDM4E
SCHEMBL2736727 0.79 CNR2 (0.56) CNR2LMNAHPGDALDH1A1HTT
SCHEMBL3859899 0.76 CNR2 (0.48) CNR2HPGDALDH1A1RAB9ANPC1
SCHEMBL250298 0.73 CNR2 (0.61) CNR2LMNAPOLB
SCHEMBL2736716 0.72 CNR2 (0.66) CNR2LMNADCTPP1
SCHEMBL2736732 0.72 CNR2 (0.58) CNR2LMNAHPGDALDH1A1KDM4E
SCHEMBL2736717 0.71 ELANE (0.46) CNR2RAB9ANPC1
SCHEMBL2736781 0.71 BRD4 (0.55) CNR2LMNAHPGDALDH1A1KDM4E
SCHEMBL2269604 0.70 ACLY (0.69) HPGDSMOCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027144-A1 Novel use of cannabinoid receptor agonist CNR2, CNR1, OPRM1 CNR2 1/4885LMNA 4495/4885HPGD 1765/4885
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CNR2 1/4885LMNA 3511/4885HPGD 1511/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 CNR2 2/4885LMNA 4604/4885HPGD 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.